U.S. markets closed

OncoSec Medical Incorporated (ONCS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
5.23-0.13 (-2.43%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Double Moving Average Crossover

Double Moving Average Crossover

Previous Close5.36
Open5.40
Bid5.20 x 800
Ask5.90 x 1000
Day's Range4.88 - 5.48
52 Week Range1.04 - 8.16
Volume307,366
Avg. Volume325,139
Market Cap185.173M
Beta (5Y Monthly)2.48
PE Ratio (TTM)N/A
EPS (TTM)-2.22
Earnings DateDec 11, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.13
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • OncoSec Announces Publication in Clinical Cancer Research of Data Supporting the Therapeutic Potential of Lead Product Candidate, TAVO™, in Triple Negative Breast Cancer
    PR Newswire

    OncoSec Announces Publication in Clinical Cancer Research of Data Supporting the Therapeutic Potential of Lead Product Candidate, TAVO™, in Triple Negative Breast Cancer

    OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), a late-stage biotechnology company focused on cytokine-based intratumoral immunotherapies, today announced the publication of research demonstrating the ability of its lead candidate TAVO™ (tavokinogene telseplasmid), a DNA-based interleukin-12 (IL-12), to activate tumor antigen specific antitumor immunity in patients with triple negative breast cancer (TNBC) in the peer-reviewed medical journal Clinical Cancer Research, a journal of the American Association for Cancer Research. The manuscript by Melinda L. Telli, M.D. et al. is titled, "Intratumoral plasmid IL-12 expands CD8+ T cells and induces a CXCR3 gene signature in triple-negative breast tumors that sensitizes patients to anti-PD-1 therapy," and is available online.

  • OncoSec Announces Approval of $2.5 Million in NJEDA NOL Program Tax Benefits
    PR Newswire

    OncoSec Announces Approval of $2.5 Million in NJEDA NOL Program Tax Benefits

    OncoSec Medical Incorporated ("OncoSec") (Nasdaq:ONCS), a late-stage biotechnology company focused on designing, developing and commercializing innovative therapies and proprietary medical approaches to stimulate and to guide an anti-tumor immune response for the treatment of cancer, today announced the approval of $2.5 million in tax credit certificates from the New Jersey Economic Development Authority (NJEDA).

  • OncoSec Appoints Bridget O'Keeffe, Ph.D. as Vice President of Clinical Development
    PR Newswire

    OncoSec Appoints Bridget O'Keeffe, Ph.D. as Vice President of Clinical Development

    OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced the appointment of Bridget O'Keeffe, Ph.D., a biotech industry veteran with more than 15 years of experience, as Vice President of Clinical Development effective February 18, 2021.